Stef Smith Research Grant supports early investigators studying the cause, diagnosis, or non-pharmacological management of myasthenia gravis to improve patients’ lives and advance scientific knowledge.
UCB removed the Stef Smith Research Grant’s “Proposals open” listing, including its February and October 2026 submission deadlines, funding details, eligibility criteria and application instructions. The page now features a separate seizure-education funding opportunity; no replacement dates for Stef Smith are provided.
Funder: UCB
Due Dates (Anticipated): February 2027 (Phase 1) | October 2027 (Phase 2)
Funding Amounts: Up to €200,000 per project, capped at €100,000 annually for up to two years; one or two awards
Summary: Supports early investigators researching the cause, diagnosis, or non-pharmacological management of myasthenia gravis.
Key Information: Organizations must apply; project leads must hold an M.D. or equivalent, be no higher than Assistant Professor, and be within five years post-neurology training.
The Stef Smith Research Grant, also known as the Stef Smith Early Investigators Research Grant, is a UCB programme supporting innovative research into the cause, diagnosis, or management of myasthenia gravis. Pharmacological treatments are excluded. It supports early investigators working through healthcare organizations or institutions, with the aim of improving patients’ lives and advancing scientific knowledge.
The grant was founded in honor of Stef Smith, whose experience inspired the myasthenia gravis research of her husband, Bryan Smith. A retired UCB researcher and biochemist, he helped discover and develop novel approaches to treating generalized myasthenia gravis. The programme carries that inspiration forward through research reviewed by the UCB Grant Review Committee.